Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 7/20 | 0.44 |
| ▸ | NPY4R | P50391 | 11/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.44 |
| ▸ | NPY1R | P25929 | 8/20 | 0.44 |
| ▸ | NPY2R | P49146 | 5/20 | 0.44 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.43 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7110412 | 0.88 | NPY4R (0.43) | NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL7113842 | 0.87 | NPY4R (0.44) | NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL7116695 | 0.87 | NPY4R (0.44) | NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL7113098 | 0.86 | NPY4R (0.44) | NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL7117913 | 0.86 | NPY4R (0.46) | NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL7116210 | 0.85 | NPY4R (0.49) | NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL7123004 | 0.85 | NPY4R (0.46) | NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL7118873 | 0.85 | NPY4R (0.42) | NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL7131237 | 0.83 | PSMB5 (0.47) | NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL7111184 | 0.83 | NPY4R (0.46) | NPY4RNPY5RNPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030176314-A1 | Compounds for the treatment of pain | H. LUNDBECK A/S (DK) | 2003-09-18 | — | — | US | disclosed |
| US-20030144310-A1 | Molecules specific for NPFF receptors and uses thereof | H. LUNDBECK A/S (DK) | 2003-07-31 | — | — | US | disclosed |
| WO-2003026657-A1 | COMPOUNDS FOR THE TREATMENT OF PAIN | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
| WO-2003026575-A2 | MOLECULES SPECIFIC FOR NPFF RECEPTORS AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176314-A1 | Compounds for the treatment of pain | NPFFR2, NPFFR1, OPRL1 | BCL2 4113/4885NPY4R 137/4885NPY5R 159/4885 |
| US-20030144310-A1 | Molecules specific for NPFF receptors and uses thereof | NPFFR1, NPFFR2, NPBWR1 | BCL2 2878/4885NPY4R 240/4885NPY5R 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.